tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Tourmaline Bio downgraded to Neutral from Overweight at Piper Sandler
PremiumThe FlyTourmaline Bio downgraded to Neutral from Overweight at Piper Sandler
1M ago
Tourmaline Bio downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Tourmaline Bio downgraded to Neutral from Buy at H.C. Wainwright
1M ago
Tourmaline Bio downgraded to Hold from Buy at Truist
Premium
The Fly
Tourmaline Bio downgraded to Hold from Buy at Truist
1M ago
Hold Rating Maintained Amidst Novartis’s Strategic Acquisition of Tourmaline Bio: Balancing Opportunities and Risks
PremiumRatingsHold Rating Maintained Amidst Novartis’s Strategic Acquisition of Tourmaline Bio: Balancing Opportunities and Risks
1M ago
Tourmaline Bio downgraded to Neutral from Buy at Guggenheim
Premium
The Fly
Tourmaline Bio downgraded to Neutral from Buy at Guggenheim
1M ago
Tourmaline Bio downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
Tourmaline Bio downgraded to Neutral from Outperform at Wedbush
1M ago
Tourmaline Bio’s Pacibekitug: A Promising Contender in ASCVD Treatment with Undervalued Potential
PremiumRatingsTourmaline Bio’s Pacibekitug: A Promising Contender in ASCVD Treatment with Undervalued Potential
1M ago
Tourmaline Bio presents data from ongoing Phase 2 TRANQUILITY trial
Premium
The Fly
Tourmaline Bio presents data from ongoing Phase 2 TRANQUILITY trial
2M ago
Tourmaline Bio’s Strategic Advancements and Promising Clinical Trial Results Reinforce Buy Rating
Premium
Ratings
Tourmaline Bio’s Strategic Advancements and Promising Clinical Trial Results Reinforce Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100